1[1]Kao JH, Chen DS. Global control of hepatitis B virus infection.Lancet Infect Dis 2002; 2:395-403
2[2]Leung N. Treatment of chronic hepatitis B: case selection and duration of therapy. J Gastroenterol Hepatol 2002; 17:409-414
3[3]Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000-summary of a workshop. Gastroenterology 2001;120:1828-1853
4[4]Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001;34:1225-1241
5[5]Perrillo R, Schiff E, Yoshida E, Statler A, Hirsch K, Wright T,Gutfreund K, Lamy P, Murray A. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants.Hepatology 2000; 32:129-134
6[6]Dienstag JL, Schiff ER, Wright TJ, Perrillo RP, Hann HW,Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M,Brown NA. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999; 341:1256-1263
7[7]Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. A oneyear trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339:61-68
8[8]Lee CM, Ong GY, Lu SN, Wang JH, Liao CA, Tung HD, Chen TM, Changchien CS. Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation. J Hepatol 2002; 37:669-674
9[9]Song BC, Suh DJ, Lee HC, Chung YH, Lee YS. Hepatitis Be antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea. Hepatology 2000;32(4 Pt 1): 803-806
10[10]Hadziyannis SJ, Papatheodoridis GV, Dimou E, Laras A,Papaioarmou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32(4 Pt 1): 847-851
5World Health Organization. Hepatitis B. World Health Organization Fact Sheet 204 dex. (Revised October 2000). WHO Web site. http:// www.who.int/mediacentreg factsheets/fs204/en/in html.
6陆文斌潘祥林.诊断学[M].7版.北京:人民卫生出版社,2007:368.
7Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatme-nt in patients with chronic hepatitis B [J]. Gastroenterology, 2003, 125: 1714-1722.
8Lai CL, Chien RN, Leung NW, etal. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group [J]. N Engl J Med, 1998, 339: 61-68.
9Liaw YF, Leung NW, Chang TT, et al. Effects of extended lamivudine the-mpy in Asian patients with chronic hepatitis B. Asia Hepatitis La- mivudine Study Group [J]. Gastroenterology, 2000, 119: 172-180.
10Dienstag JL, SchiffER, Wright TL, et al. Lamivudine as initial treat- ment for chronic hepatitis B in the United States [J]. N Engl J Med, 1999, 341: 1256-1263.
